GP KFPs / SAQs · gastrointestinal-health
Irritable bowel syndrome — KFP-style written assessment
KFP-style staged scenarios on irritable bowel syndrome: making the positive Rome IV diagnosis with the limited mandatory battery, red flags, subtype-based therapy (psyllium/linaclotide; loperamide/rifaximin/SeHCAT; amitriptyline), staged low-FODMAP dieting under supervision, and gut-brain CBT.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
IBS: diagnose positively, test narrowly, treat by subtype — and keep checking the flags
KFP 1 (10 marks)
A 29-year-old marketing assistant reports two years of lower abdominal cramping relieved by opening her bowels, bloating by evening, and stool alternating between pellet-like and loose. Symptoms daily. No weight loss, no nocturnal diarrhoea, no bleeding. Examination and bloods normal. [18]
- State the diagnosis and its formal criteria basis. (3) [18]
- Which tests are required before confirming, and which are not? (4) [18] [2]
- She asks 'how can you be sure it's not something serious?' Answer using the limited-test strategy evidence. (3) [2]
Model answers
- Irritable bowel syndrome, diagnosed positively on Rome criteria: recurrent abdominal pain/discomfort relieved by defecation or associated with altered bowel frequency or form, plus supportive features (bloating, altered passage), for at least six months. NICE frames assessment when pain, bloating or bowel-habit change persists ≥6 months; Rome IV requires symptom onset ≥6 months with recurrence over the last three. [18] [18]
- Required for everyone meeting criteria: FBC, CRP or ESR/plasma viscosity, and coeliac serology (tTG ± EMA); faecal calprotectin where IBD is plausible. NOT required: colonoscopy, sigmoidoscopy, ultrasound, barium enema, thyroid function, faecal occult blood, ova/parasites, hydrogen breath tests — these belong only where red flags arise. Her normal bloods already satisfy most of the battery; add coeliac serology and consider calprotectin. [18]
- The biomarker data make a confident positive diagnosis legitimate: with calprotectin ≤40 µg/g and CRP ≤0.5 mg/L the probability of IBD falls below one percent, so adding CRP and calprotectin to Rome symptoms permits confident diagnosis while sparing colonoscopy and its harms. Red-flag absence (no bleeding, weight loss, anaemia, nocturnal symptoms) completes the picture. [2]
References9ShowHide
- [2]Menees SB, Powell C, Kurlander J et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. The American journal of gastroenterology, 2015.PMID 25732419
- [4]Staudacher HM, Rucco V, Mancell S et al. Fiber supplementation in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Gastroenterology, 2026.PMID 42600900
- [6]Ford AC, Wright-Hughes A, Alderson SL et al. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS). Lancet, 2023.PMID 37858323
- [7]Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. The New England journal of medicine, 2011.PMID 21208106
- [9]Rao S, Lembo AJ, Shiff SJ et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. The American journal of gastroenterology, 2012.PMID 22986440
- [10]Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology, 2014.PMID 24076059
- [12]Wallén H, Lindfors P, Andersson E et al. Return on investment of internet delivered exposure therapy for irritable bowel syndrome: a randomized controlled trial. BMC gastroenterology, 2021.PMID 34256715
- [18]National Institute for Health and Care Excellence Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. BMJ, 2008.PMID 18325967
- [16]Dilmaghani S, BouSaba J, Lupianez-Merly C et al. Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea. Alimentary pharmacology & therapeutics, 2025.PMID 41090475